3 months ago
2
Zydus Lifesciences has launched Anyra, a biosimilar of Regeneron Pharmaceuticals’ Aflibercept 2 mg that is indicated for definite oculus diseases.
Anyra is India’s archetypal indigenously developed biosimilar of Aflibercept 2 mg, Zydus said connected Thursday, announcing it has besides signed an statement with Regeneron Pharmaceuticals and Bayer.
Anyra is indicated for attraction of neovascular (wet) Age-related Macular Degeneration, ocular impairment owed to macular edema secondary to Retinal Vein Occlusion, ocular impairment owed to Diabetic Macular Edema (DME) and a fewer different conditions. Collectively, the conditions correspond a ample diligent excavation requiring timely anti-VEGF therapy to forestall irreversible imaginativeness loss. As chronic retinal diseases necessitate repeated intravitreal injections implicit extended periods, affordability and continuity of attraction are of concern, the institution said.
“Anyra is simply a transformative measurement for affordable retinal attraction successful India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding diligent entree to captious therapies with precocious biologics,” Zydus Lifesciences managing manager Sharvil P. Patel said.
